Novo Nordisk has presented interim data showing that its coagulant NovoEight is safe and effective in preventing and treating bleeds in people with severe haemophilia A in the long term.

In previously treated patents given the preventive regimen, 90% of all bleeding episodes were successfully dealt with with one or two infusions of NovoEight (turoctocog alfa), early findings of the Phase III trial show.

Around 142,000 people around the globe are estimated to have haemophilia, and “finding new treatments effective at preventing bleeding episodes long-term is essential,” noted Margareth Ozelo, IHTC Hemocentro Unicamp, University of Campinas, Sao Paulo, Brazil.

The drug was approved in Europe and the US back in 2013 for use in adults and children with haemophilia A for the control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. But the drug was only launched in the US in March this year, following expiration of a third-party patent.